Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism

JAMA

Volumn 296, Issue 8, 2006, Pages 935-942

  Kearon, Clive ^a,b,e   Ginsberg, Jeffrey S ^a,b   Julian, Jim A ^a,b   Douketis, James ^a,b   Solymoss, Susan ^c   Ockelford, Paul ^d   Jackson, Sharon ^d   Turpie, Alexander G ^a,b   MacKinnon, Betsy ^a,b   Hirsh, Jack ^a,b   Gent, Michael ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b HENDERSON RESEARCH CENTRE   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d UNIVERSITY OF AUCKLAND   (New Zealand)

^e HAMILTON HEALTH SCIENCES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN; ANTICOAGULANT AGENT;

ACUTE DISEASE; ADULT; AGED; ARTICLE; BLEEDING; CANADA; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DEEP VEIN THROMBOSIS; DEMOGRAPHY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FATALITY; DRUG LABELING; DRUG SAFETY; FEMALE; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; NEW ZEALAND; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UNIVERSITY HOSPITAL; VENOUS THROMBOEMBOLISM; AMBULATORY CARE; DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; PARTIAL THROMBOPLASTIN TIME; SUBCUTANEOUS DRUG ADMINISTRATION; VEIN THROMBOSIS;

AGED; AMBULATORY CARE; ANTICOAGULANTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; PULMONARY EMBOLISM; VENOUS THROMBOSIS;

EID: 33747592631     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.296.8.935     Document Type: Article

References (32)

1. Buller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 suppl):401S-428S.
2. O'Brien B, Levine M, Willan A, et al. Economic evaluation of outpatient treatment with low-molecular-weight heparin for proximal vein thrombosis. Arch Intern Med. 1999;159:2298-2304.
3. Hommes DW, Bura A, Mazzolai L, Buller HR, ten Cate JW. Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis. Ann Intern Med. 1992;116:279-284.
4. Prandoni P, Carnovali M, Marchiori A. Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism. Arch Intern Med. 2004;164:1077-1083.
5. Bates SM, Weitz JI, Johnston M, Hirsh J, Ginsberg JS. Use of a fixed activated partial thromboplastin time ratio to establish a therapeutic range for unfractionated heparin. Arch Intern Med. 2001;161:385-391.
6. Kearon C, Johnston M, Moffat K, McGinnis J, Ginsberg JS. Effect of warfarin on activated partial thromboplastin time in patients receiving heparin. Arch Intern Med. 1998;158:1140-1143.
7. Basu D, Gallus AS, Hirsh J, Cade J. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med. 1972;287:324-327.
8. Hull RD, Raskob GE, Brant RF, Pineo GF, Valentine KA. Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis. Arch Intern Med. 1997;157:2562-2568.
9. Hull RD, Raskob G, Brant RF, Pineo GF, Valentine KA. The importance of initial heparin treatment on long-term clinical outcomes of antithrombotic therapy. Arch Intern Med. 1997;157:2317-2321.
10. Anand S, Ginsberg JS, Kearon C, Gent M, Hirsh J. The relation between the activated partial thromboplastin time response and recurrence in patients with venous thrombosis treated with continuous intravenous heparin. Arch Intern Med. 1996;156:1677-1681.
11. Anand SS, Bates S, Ginsberg JS, et al. Recurrent venous thrombosis and heparin therapy: an evaluation of the importance of early activated partial thromboplastin time results. Arch Intern Med. 1999;159:2029-2032.
12. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 Suppl):188S-203S.
13. Hull RD, Raskob GE, Rosenbloom D, et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med. 1990;322:1260-1264.
14. Levine MN, Raskob G, Beyth RJ, Kearon C, Schulman S. Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 suppl):287S-310S.
15. Raschke RA, Reilly BM, Guidry JR, Fontana JR, Srinivas S. The weight-based heparin dosing nomogram compared with a "standard care" nomogram. Ann Intern Med. 1993;119:874-881.
16. Kearon C, Julian JA, Newman TE, Ginsberg JS; for the McMaster Diagnostic Imaging Practice Guidelines Initiative. Non-invasive diagnosis of deep vein thrombosis. Ann Intern Med. 1998;128:663-677.
17. Fedullo PF, Tapson VF. Clinical practice. The evaluation of suspected pulmonary embolism. N Engl J Med. 2003;349:1247-1256.
18. Kearon C, Harrison L, Crowther M, Ginsberg JS. Optimal dosing of subcutaneous unfractionated heparin for the treatment of deep vein thrombosis. Thromb Res. 2000;97:395-403.
19. Hull RD, Raskob GE, Hirsh J, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med. 1986;315:1109-1114.
20. Kearon C, Ginsberg JS, Kovacs MJ, et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med. 2003;349:631-639.
21. Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med. 1996;334:677-681.
22. Koopman MMW, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med. 1996;334:682-687.
23. The Columbus Investigators. Low molecular weight heparin is an effective and safe treatment for deep-vein thrombosis and pulmonary embolism. N Engl J Med. 1997;337:657-662.
24. Farrington CP, Manning G. Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk. Stat Med. 1990;9:1447-1454.
25. Gould MK, Dembitzer AD, Sanders GD, Garber AM. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis [see comments]. Ann Intern Med. 1999;130:789-799.
26. Fleming T, ed. Red Book 2006. Montvale, NJ: Thompson PDR; 2006.
27. Buller HR, Davidson BL, Decousus H, et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med. 2003;349:1695-1702.
28. Buller HR, Davidson BL, Decousus H, et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med. 2004;140:867-873.
29. Fiessinger JN, Huisman MV, Davidson BL, et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA. 2005;293:681-689.
30. Schulz KF, Grimes DA. Allocation concealment in randomised trials: defending against deciphering. Lancet. 2002;359:614-618.
31. Couturaud F, Julian JA, Kearon C. Low molecular weight heparin administered once versus twice daily in patients with venous thromboembolism: a meta-analysis. Thromb Haemost. 2001;86:980-984.
32. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349:146-153.